TY - JOUR
T1 - Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals
AU - Suh, Hyeon Sook
AU - Lo, Yungtai
AU - Choi, Namjong
AU - Letendre, Scott
AU - Lee, Sunhee C.
N1 - Funding Information:
This study was supported by the NIH grants K01MH084705, R01MH55477, Einstein CFAR (P30AI051519), and the CNS HIV Antiretroviral Therapy Effects Research (CHARTER). We are grateful to Robin Squeglia at the Einstein Biomarker Analytic Research Core (BARC) Laboratory for assisting with the IGF assays and Dr. Susan Morgello for her support throughout the study. CHARTER was supported by the NIH grants N01 MH22005, HHSN271201000036C, and HHSN271201000030C. The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Government. The CNS HIV Antiretroviral Therapy Effects Research (CHARTER) group is affiliated with Johns Hopkins University; the Icahn School of Medicine at Mount Sinai; University of California, San Diego; University of Texas, Galveston; University of Washington, Seattle; Washington University, St. Louis; and is headquartered at the University of California, San Diego and includes: Director: Igor Grant, M.D.; Co-Directors: Scott L. Letendre, M.D., Ronald J. Ellis, M.D., Ph.D., Thomas D. Marcotte, Ph.D.; Center Manager: Donald Franklin, Jr.; Neuromedical Component: Ronald J. Ellis, M.D., Ph.D. (P.I.), J. Allen McCutchan, M.D.; Laboratory and Virology Component: Scott Letendre, M.D. (Co-P.I.), Davey M. Smith, M.D. (Co-P.I.).; Neurobehavioral Component: Robert K. Heaton, Ph.D. (P.I.), J. Hampton Atkinson, M.D., Matthew Dawson; Imaging Component: Christine Fennema-Notestine, Ph.D. (P.I.), Michael J Taylor, Ph.D., Rebecca Theilmann, Ph.D.; Data Management Component: Anthony C. Gamst, Ph.D. (P.I.), Clint Cushman; Statistics Component: Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D., Reena Deutsch, Ph.D.; Johns Hopkins University Site: Justin McArthur (P.I.), Vincent Rogalski; Icahn School of Medicine at Mount Sinai Site: Susan Morgello, M.D. (Co-P.I.) and David Simpson, M.D. (Co-P.I.), Letty Mintz, N.P.; University of California, San Diego Site: J. Allen McCutchan, M.D. (P.I.), Kaori Phillips, B.S.N.; University of Washington, Seattle Site: Ann Collier, M.D. (Co-P.I.) and Christina Marra, M.D. (Co-P.I.), Trudy Jones, M.N., A.R.N.P.; University of Texas, Galveston Site: Benjamin Gelman, M.D., Ph. D. (P.I.), Eleanor Head, R.N., B.S.N.; and Washington University, St. Louis Site: David Clifford, M.D. (P.I.), Muhammad Al-Lozi, M.D., Mengesha Teshome, M.D.
Publisher Copyright:
© 2015 Suh et al.; licensee BioMed Central.
PY - 2015/4/15
Y1 - 2015/4/15
N2 - Background: Clinically significant dysregulation of the insulin-like growth factor (IGF) family proteins occurs in HIV-infected individuals, but the details including whether the deficiencies in IGFs contribute to CNS dysfunction are unknown. Methods: We measured the levels of IGF1, IGF2, IGFBP1, IGFBP2, and IGF2 receptor (IGF2R) in matching plasma and cerebrospinal fluid (CSF) samples of 107 HIV+ individuals from CNS HIV Antiretroviral Therapy Effects Research (CHARTER) and analyzed their associations with demographic and disease characteristics, as well as levels of several soluble inflammatory mediators (TNFα, IL-6, IL-10, IL-17, IP-10, MCP-1, and progranulin). We also determined whether IGF1 or IGF2 deficiency is associated with HIV-associated neurocognitive disorder (HAND) and whether the levels of soluble IGF2R (an IGF scavenging receptor, which we also have found to be a cofactor for HIV infection in vitro) correlate with HIV viral load (VL). Results: There was a positive correlation between the levels of IGF-binding proteins (IGFBPs) and those of inflammatory mediators: between plasma IGFBP1 and IL-17 (α coefficient 0.28, P=0.009), plasma IGFBP2 and IL-6 (α coefficient 0.209, P=0.021), CSF IGFBP1 and TNFα (α coefficient 0.394, P<0.001), and CSF IGFBP2 and TNF-α (α coefficient 0.14, P<0.001). As IGFBPs limit IGF availability, these results suggest that inflammation is a significant factor that modulates IGF protein expression/availability in the setting of HIV infection. However, there was no significant association between HAND and the reduced levels of plasma IGF1, IGF2, or CSF IGF1, suggesting a limited power of our study. Interestingly, plasma IGF1 was significantly reduced in subjects on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART) compared to protease inhibitor-based therapy (174.1±59.8 vs. 202.8±47.3ng/ml, P=0.008), suggesting a scenario in which ART regimen-related toxicity can contribute to HAND. Plasma IGF2R levels were positively correlated with plasma VL (α coefficient 0.37, P=0.021) and inversely correlated with current CD4+ T cell counts (α coefficient -0.04, P=0.021), supporting our previous findings in vitro. Conclusions: Together, these results strongly implicate (1) an inverse relationship between inflammation and IGF growth factor availability and the contribution of IGF deficiencies to HAND and (2) the role of IGF2R in HIV infection and as a surrogate biomarker for HIV VL.
AB - Background: Clinically significant dysregulation of the insulin-like growth factor (IGF) family proteins occurs in HIV-infected individuals, but the details including whether the deficiencies in IGFs contribute to CNS dysfunction are unknown. Methods: We measured the levels of IGF1, IGF2, IGFBP1, IGFBP2, and IGF2 receptor (IGF2R) in matching plasma and cerebrospinal fluid (CSF) samples of 107 HIV+ individuals from CNS HIV Antiretroviral Therapy Effects Research (CHARTER) and analyzed their associations with demographic and disease characteristics, as well as levels of several soluble inflammatory mediators (TNFα, IL-6, IL-10, IL-17, IP-10, MCP-1, and progranulin). We also determined whether IGF1 or IGF2 deficiency is associated with HIV-associated neurocognitive disorder (HAND) and whether the levels of soluble IGF2R (an IGF scavenging receptor, which we also have found to be a cofactor for HIV infection in vitro) correlate with HIV viral load (VL). Results: There was a positive correlation between the levels of IGF-binding proteins (IGFBPs) and those of inflammatory mediators: between plasma IGFBP1 and IL-17 (α coefficient 0.28, P=0.009), plasma IGFBP2 and IL-6 (α coefficient 0.209, P=0.021), CSF IGFBP1 and TNFα (α coefficient 0.394, P<0.001), and CSF IGFBP2 and TNF-α (α coefficient 0.14, P<0.001). As IGFBPs limit IGF availability, these results suggest that inflammation is a significant factor that modulates IGF protein expression/availability in the setting of HIV infection. However, there was no significant association between HAND and the reduced levels of plasma IGF1, IGF2, or CSF IGF1, suggesting a limited power of our study. Interestingly, plasma IGF1 was significantly reduced in subjects on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART) compared to protease inhibitor-based therapy (174.1±59.8 vs. 202.8±47.3ng/ml, P=0.008), suggesting a scenario in which ART regimen-related toxicity can contribute to HAND. Plasma IGF2R levels were positively correlated with plasma VL (α coefficient 0.37, P=0.021) and inversely correlated with current CD4+ T cell counts (α coefficient -0.04, P=0.021), supporting our previous findings in vitro. Conclusions: Together, these results strongly implicate (1) an inverse relationship between inflammation and IGF growth factor availability and the contribution of IGF deficiencies to HAND and (2) the role of IGF2R in HIV infection and as a surrogate biomarker for HIV VL.
KW - Biomarker
KW - Charter
KW - Cytokines
KW - Growth factor
KW - Neurocognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=84949120165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949120165&partnerID=8YFLogxK
U2 - 10.1186/s12974-015-0288-6
DO - 10.1186/s12974-015-0288-6
M3 - Article
C2 - 25890304
AN - SCOPUS:84949120165
SN - 1742-2094
VL - 12
JO - Journal of Neuroinflammation
JF - Journal of Neuroinflammation
IS - 1
M1 - 72
ER -